ClinicalTrials.gg
RecruitingNCT07542431VCRMUpdated Nov 12, 2026

Impact of Dog Adoption and Training in Veterans With Post-traumatic Stress Symptoms and/or Other Mental Health Conditions

An interventional study of Dog training in Posttraumatic Stress Symptoms and Mental Health Conditions, sponsored by Florida Atlantic University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Florida Atlantic University · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this single-arm study is to learn if a dog adoption and training program can treat, prevent in [describe participant population/primary condition; could include any of the following: sex/gender, age groups, healthy volunteers]. The main questions it aims to answer are:

  • Does the dog adoption and training program decrease posttraumatic stress symptoms in veterans with self-reported posttraumatic stress symptoms?
  • Does the dog adoption and training program decrease stress and improve psychosocial health in veterans with self-reported posttraumatic stress symptoms?
  • Does the dog adoption and training program decrease inflammation, increase oxytocin, and change the structure and resting-state function of specific brain regions in veterans with self-reported posttraumatic stress symptoms?

Participants will:

  • Attend eight one-hour professional dog training sessions within a 10-week period.
  • Visit the clinical research unit four times during the study for data collection.
02

Conditions studied

  • Posttraumatic Stress Symptoms
  • Mental Health Conditions
03

In context

Lead sponsor

Florida Atlantic University is the lead sponsor of 36 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Military veteran with self-reported posttraumatic stress symptoms and/or other mental health conditions
  • Over 18 years of age
  • Applied and approved to adopt a shelter dog for training through the Humane Society of Broward County in Fort Lauderdale, Florida
  • English speaker (written and spoken)
  • Home internet access via tablet, computer or smartphone.

Exclusion criteria

Exclusion Criteria:

  • Fear of dogs
  • Allergies to pet dander
  • Uncorrected hearing or visual impairment.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Study Intervention

    Within-subjects design

    Other: Dog training

Interventions

  • OtherDog training

    Eight, one-hour professional dog training sessions over 8-10 weeks

06

What researchers measure

Primary outcomes

  1. Change in self-reported posttraumatic stress disorder (PTSD) symptoms from baseline to 4 weeks post-intervention

    Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report measure of PTSD symptoms with scores ranging from 0 to 80.

    Time frame: From enrollment to 4 weeks post-intervention

Secondary outcomes

  1. Change in depression symptom severity from baseline to 4 weeks post-intervention

    Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report measure of depressive symptoms with scores ranging from 0 to 27.

    Time frame: From enrollment to 4 weeks post-intervention

  2. Change in anxiety symptom severity from baseline to 4 weeks post-intervention

    Generalized Anxiety Disorder-7 (GAD-7) is a is a 7-item self-report measure of anxiety symptoms with scores ranging from 0 to 21.

    Time frame: From enrollment to 4 weeks post-intervention

  3. Change in perceived stress severity from baseline to 4 weeks post-intervention

    Perceived Stress Scale-10 (PSS-10) is a 10-item self-report measure of perceived stress symptoms with scores ranging from 0 to 40.

    Time frame: From enrollment to 4 weeks post-intervention

  4. Change in sleep disturbance from baseline to 4 weeks post-intervention

    Patient-Reported Outcomes Measurement Information System Sleep 8b (PROMIS Sleep 8b) is an 8-item self-report measure of sleep quality over the past 7 days with raw scores ranging from 8 to 40 and standardized T scores ranging from 28.9 to 76.5.

    Time frame: From enrollment to 4 weeks post-intervention

  5. Change in loneliness from baseline to 4 weeks post-intervention

    Revised UCLA Loneliness Scale is a 20-item self-report measure of loneliness with scores ranging from 20 to 80.

    Time frame: From enrollment to 4 weeks post-intervention

  6. Change in alcohol use from baseline to 4 weeks post-intervention

    Alcohol Use Disorder Identification Test (AUDIT) is a 10-item self-report measure of alcohol use with scores ranging from 0 to 40.

    Time frame: From enrollment to 4 weeks post-intervention

  7. Change in cannabis use from baseline to 4 weeks post-intervention

    Cannabis Use Disorder Identification Test (CUDIT) is an 8-item self-report measure of cannabis use with scores ranging from 0 to 32.

    Time frame: From enrollment to 4 weeks post-intervention

  8. Change in salivary oxytocin levels from baseline to 4 weeks post-intervention

    Oxytocin is a neurotransmitter that plays a role in determining social behavior. Salivary oxytocin levels range from 6.4-1000 pg/mL.

    Time frame: From enrollment to 4 weeks post-intervention

  9. Change in Interleukin-1 beta (IL-1β) from baseline to 4 weeks post-intervention

    IL-1β is a pro-inflammatory cytokine found to be higher in individuals with PTSD compared to healthy controls. IL-1β is measured via capillary blood obtained via fingerstick.

    Time frame: From enrollment to 4 weeks post-intervention

  10. Change in Interleukin-6 (IL-6) from baseline to 4 weeks post-intervention

    IL-6 is a pro-inflammatory cytokine found to be higher in individuals with PTSD compared to healthy controls. IL-6 is measured via capillary blood obtained via fingerstick.

    Time frame: From enrollment to 4 weeks post-intervention

  11. Change in tumor necrosis factor-alpha (TNF-alpha) from baseline to 4 weeks post-intervention

    TNF-alpha is a pro-inflammatory cytokine found to be higher in individuals with PTSD compared to healthy controls. TNF-alpha is measured via capillary blood obtained via fingerstick.

    Time frame: From enrollment to 4 weeks post-intervention

Other outcomes

  1. Change in alcohol demand for participants who answer "yes" to alcohol consumption in the AUDIT measure from baseline to 4 weeks post-intervention

    Alcohol Purchase Task is a tool to measure alcohol demand by asking individuals how many drinks they would consume at prices ranging from free to high, using behavioral economic indices for scoring.

    Time frame: From enrollment to 4 weeks post-intervention

  2. Change in cannabis demand for participants who answer "yes" to cannabis use from baseline to 4 weeks post-intervention

    Cannabis Purchase Task is a tool to measure cannabis demand by assessing how much an individual purchases at increasing prices.

    Time frame: From enrollment to 4 weeks post-intervention

  3. Change in Magnetic Resonance Imaging (MRI) biomarkers from baseline to 4 weeks post-intervention

    Optional participation in an MRI to detect changes in the structure and resting-state function of specific brain regions (anterior cingulate, amygdala, hippocampus, and insula)

    Time frame: Pre-intervention and 4 weeks post-intervention

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2030, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 21, 2026
StartActual
Feb 9, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact's phone or email changed: •••4912→•••4227. See the current contact
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Contact Study contact's phone or email changed: •••4912→•••4227. See the current contact
    + 3 other changes: verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07542431
Lead sponsor
Florida Atlantic University
Responsible party
Beth Pratt (Associate Professor, Florida Atlantic University) — Principal investigator
First posted
Apr 21, 2026
Start date
Feb 9, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Nov 12, 2026

Study contacts

Beth A Pratt, PhD
Contact
bpratt4@health.fau.edu
561-297-4227
Beth A Pratt, PhD
principal investigator · Florida Atlantic University
Cheryl A Krause-Parello, PhD
principal investigator · Florida Atlantic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion